{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:34:43Z","timestamp":1793313283054,"version":"4.5.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Science and Technology Major Project for Infectious Diseases Control and Prevention","award":["No.2017ZX10201301-006"],"award-info":[{"award-number":["No.2017ZX10201301-006"]}]},{"name":"CAMS Major Innovation Funding For Medical Science","award":["2016-I2M-2-006"],"award-info":[{"award-number":["2016-I2M-2-006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10096-020-03843-6","type":"journal-article","created":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T09:03:49Z","timestamp":1594199029000},"page":"1405-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Tuberculosis vaccine development: from classic to clinical candidates"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-3375","authenticated-orcid":false,"given":"Junli","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"issue":"10","key":"3843_CR1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3389\/fgene.2019.00865","volume":"18","author":"W Correa-Macedo","year":"2019","unstructured":"Correa-Macedo W et al (2019) The interplay of human and Mycobacterium tuberculosis Genomic Variability. Front Genet 18(10):865","journal-title":"Front Genet"},{"issue":"Suppl 1","key":"3843_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000086182","volume":"14","author":"AS Mustafa","year":"2005","unstructured":"Mustafa AS (2005) Mycobacterial gene cloning and expression, comparative genomics, bioinformatics and proteomics in relation to the development of new vaccines and diagnostic reagents. Med Princ Pract 14(Suppl 1):27\u201334","journal-title":"Med Princ Pract"},{"issue":"Suppl 1","key":"3843_CR3","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.tube.2015.02.021","volume":"95","author":"I Hershkovitz","year":"2015","unstructured":"Hershkovitz I et al (2015) Tuberculosis origin: the Neolithic scenario. Tuberculosis (Edinb) 95(Suppl 1):S122\u2013S126","journal-title":"Tuberculosis (Edinb)"},{"key":"3843_CR4","volume-title":"Global tuberculosis report 2019","author":"World Health Organization","year":"2019","unstructured":"World Health Organization (2019) Global tuberculosis report 2019. WHO, Geneva"},{"key":"3843_CR5","volume-title":"TB: a global emergency, WHO report on the TB epidemic (WHO\/TB\/94.177)","author":"World Health Organization","year":"1994","unstructured":"World Health Organization (1994) TB: a global emergency, WHO report on the TB epidemic (WHO\/TB\/94.177). WHO, Geneva"},{"issue":"1","key":"3843_CR6","first-page":"137","volume":"41","author":"K Styblo","year":"1969","unstructured":"Styblo K, Meijer J, Sutherland I (1969) The transmission of tubercle bacilli: its trend in a human population. Bull World Health Organ 41(1):137\u2013178","journal-title":"Bull World Health Organ"},{"issue":"9","key":"3843_CR7","first-page":"879","volume":"5","author":"P D'Arcy Hart","year":"2001","unstructured":"D'Arcy Hart P (2001) Historical declines in tuberculosis: nature, nurture and the biosocial model. Int J Tuberc Lung Dis 5(9):879","journal-title":"Int J Tuberc Lung Dis"},{"key":"3843_CR8","doi-asserted-by":"crossref","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","volume":"2","author":"M Pai","year":"2016","unstructured":"Pai M et al (2016) Tuberculosis. Nat Rev Dis Primers 2:16076","journal-title":"Nat Rev Dis Primers"},{"key":"3843_CR9","doi-asserted-by":"publisher","unstructured":"Schorey JS, Schlesinger LS., Innate Immune Responses to Tuberculosis. Microbiol Spectr, 2016 Dec; 4(6). https:\/\/doi.org\/10.1128\/microbiolspec.TBTB2-0010-2016","DOI":"10.1128\/microbiolspec.TBTB2-0010-2016"},{"issue":"7470","key":"3843_CR10","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/502S8a","volume":"502","author":"S DeWeerdt","year":"2013","unstructured":"DeWeerdt S (2013) Vaccines: an age-old problem. Nature 502(7470):S8\u2013S9","journal-title":"Nature"},{"issue":"11","key":"3843_CR11","first-page":"1481","volume":"24","author":"A Calmette","year":"1931","unstructured":"Calmette A (1931) Preventive vaccination against tuberculosis with BCG. Proc R Soc Med 24(11):1481\u20131490","journal-title":"Proc R Soc Med"},{"issue":"13","key":"3843_CR12","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","volume":"104","author":"R Brosch","year":"2007","unstructured":"Brosch R et al (2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 104(13):5596\u20135601","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3843_CR13","doi-asserted-by":"crossref","first-page":"e32567","DOI":"10.1371\/journal.pone.0032567","volume":"7","author":"M Favorov","year":"2012","unstructured":"Favorov M et al (2012) Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guerin (BCG) vaccines from different sources Kazakhstan. PLoS One 7(3):e32567","journal-title":"PLoS One"},{"issue":"27\u201330","key":"3843_CR14","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1016\/S0264-410X(03)00484-5","volume":"21","author":"S Mostowy","year":"2003","unstructured":"Mostowy S et al (2003) The in vitro evolution of BCG vaccines. Vaccine 21(27\u201330):4270\u20134274","journal-title":"Vaccine"},{"issue":"9517","key":"3843_CR15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","volume":"367","author":"BB Trunz","year":"2006","unstructured":"Trunz BB, Fine P, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367(9517):1173\u20131180","journal-title":"Lancet"},{"issue":"3","key":"3843_CR16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1189\/jlb.5RI0315-096R","volume":"98","author":"BA Blok","year":"2015","unstructured":"Blok BA et al (2015) Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol 98(3):347\u2013356","journal-title":"J Leukoc Biol"},{"issue":"2","key":"3843_CR17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1586\/14760584.5.2.277","volume":"5","author":"A Roth","year":"2006","unstructured":"Roth A et al (2006) Bacillus Calmette-Guerin vaccination and infant mortality. Expert Rev Vaccines 5(2):277\u2013293","journal-title":"Expert Rev Vaccines"},{"key":"3843_CR18","doi-asserted-by":"publisher","unstructured":"Andersen P, Kaufmann SH., Novel vaccination strategies against tuberculosis.Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a018523. https:\/\/doi.org\/10.1101\/cshperspect.a018523","DOI":"10.1101\/cshperspect.a018523"},{"key":"3843_CR19","doi-asserted-by":"crossref","first-page":"d5974","DOI":"10.1136\/bmj.d5974","volume":"343","author":"LC Rodrigues","year":"2011","unstructured":"Rodrigues LC, Mangtani P, Abubakar I (2011) How does the level of BCG vaccine protection against tuberculosis fall over time? BMJ 343:d5974","journal-title":"BMJ"},{"issue":"4","key":"3843_CR20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani P et al (2014) Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58(4):470\u2013480","journal-title":"Clin Infect Dis"},{"issue":"37","key":"3843_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17370","volume":"17","author":"I Abubakar","year":"2013","unstructured":"Abubakar I et al (2013) Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guerin vaccination against tuberculosis. Health Technol Assess 17(37):1\u2013372 v-vi","journal-title":"Health Technol Assess"},{"issue":"8","key":"3843_CR22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrmicro1211","volume":"3","author":"P Andersen","year":"2005","unstructured":"Andersen P, Doherty TM (2005) The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3(8):656\u2013662","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"3843_CR23","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","author":"GA Colditz","year":"1994","unstructured":"Colditz GA et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271(9):698\u2013702","journal-title":"JAMA"},{"issue":"8986","key":"3843_CR24","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"PE Fine","year":"1995","unstructured":"Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346(8986):1339\u20131345","journal-title":"Lancet"},{"issue":"1 Pt 1","key":"3843_CR25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","volume":"96","author":"GA Colditz","year":"1995","unstructured":"Colditz GA et al (1995) The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96(1 Pt 1):29\u201335","journal-title":"Pediatrics"},{"issue":"8","key":"3843_CR26","first-page":"952","volume":"14","author":"CJ Gallant","year":"2010","unstructured":"Gallant CJ et al (2010) Impact of age and sex on mycobacterial immunity in an area of high tuberculosis incidence. Int J Tuberc Lung Dis 14(8):952\u2013959","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"3843_CR27","first-page":"819","volume":"57","author":"Trial of BCG vaccines in south India for tuberculosis prevention","year":"1979","unstructured":"Trial of BCG vaccines in south India for tuberculosis prevention (1979) first report--Tuberculosis Prevention Trial. Bull World Health Organ 57(5):819\u2013827","journal-title":"Bull World Health Organ"},{"key":"3843_CR28","volume-title":"Trial of BCG vaccines in south India for tuberculosis prevention: first report","year":"1979","unstructured":"Bulletin of the World Health Organization (1979) Trial of BCG vaccines in south India for tuberculosis prevention: first report. WHO, Geneva"},{"issue":"11","key":"3843_CR29","doi-asserted-by":"crossref","first-page":"6781","DOI":"10.4049\/jimmunol.174.11.6781","volume":"174","author":"DP Harris","year":"2005","unstructured":"Harris DP et al (2005) Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J Immunol 174(11):6781\u20136790","journal-title":"J Immunol"},{"issue":"2","key":"3843_CR30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4049\/jimmunol.172.2.954","volume":"172","author":"M Wagner","year":"2004","unstructured":"Wagner M et al (2004) IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA. J Immunol 172(2):954\u2013963","journal-title":"J Immunol"},{"issue":"10","key":"3843_CR31","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.4049\/jimmunol.173.10.6357","volume":"173","author":"J Wang","year":"2004","unstructured":"Wang J et al (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173(10):6357\u20136365","journal-title":"J Immunol"},{"issue":"8","key":"3843_CR32","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","volume":"77","author":"HM Vordermeier","year":"2009","unstructured":"Vordermeier HM et al (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77(8):3364\u20133373","journal-title":"Infect Immun"},{"issue":"11","key":"3843_CR33","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.vaccine.2013.11.045","volume":"32","author":"G Dean","year":"2014","unstructured":"Dean G et al (2014) Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 32(11):1304\u20131310","journal-title":"Vaccine"},{"issue":"20","key":"3843_CR34","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.vaccine.2018.03.068","volume":"36","author":"HJ Metcalfe","year":"2018","unstructured":"Metcalfe HJ et al (2018) Ag85A-specific CD4+ T cell lines derived after boosting BCG-vaccinated cattle with Ad5-85A possess both mycobacterial growth inhibition and anti-inflammatory properties. Vaccine 36(20):2850\u20132854","journal-title":"Vaccine"},{"issue":"8","key":"3843_CR35","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1128\/IAI.00517-06","volume":"74","author":"M Santosuosso","year":"2006","unstructured":"Santosuosso M et al (2006) Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74(8):4634\u20134643","journal-title":"Infect Immun"},{"issue":"8","key":"3843_CR36","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1586\/14760584.2014.929947","volume":"13","author":"F Smaill","year":"2014","unstructured":"Smaill F, Xing Z (2014) Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Rev Vaccines 13(8):927\u2013930","journal-title":"Expert Rev Vaccines"},{"issue":"205","key":"3843_CR37","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","volume":"5","author":"F Smaill","year":"2013","unstructured":"Smaill F et al (2013) A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 5(205):205ra134","journal-title":"Sci Transl Med"},{"issue":"12","key":"3843_CR38","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/infdis\/jiw467","volume":"214","author":"M Jeyanathan","year":"2016","unstructured":"Jeyanathan M et al (2016) Induction of an immune-protective T-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans. J Infect Dis 214(12):1996\u20132005","journal-title":"J Infect Dis"},{"issue":"48","key":"3843_CR39","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","volume":"33","author":"E Stylianou","year":"2015","unstructured":"Stylianou E et al (2015) Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A. Vaccine 33(48):6800\u20136808","journal-title":"Vaccine"},{"issue":"4","key":"3843_CR40","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","volume":"198","author":"T Hawkridge","year":"2008","unstructured":"Hawkridge T et al (2008) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 198(4):544\u2013552","journal-title":"J Infect Dis"},{"issue":"4","key":"3843_CR41","doi-asserted-by":"crossref","first-page":"ftw016","DOI":"10.1093\/femspd\/ftw016","volume":"74","author":"HM Dockrell","year":"2016","unstructured":"Dockrell HM (2016) Towards new TB vaccines: what are the challenges? Pathog Dis 74(4):ftw016","journal-title":"Pathog Dis"},{"issue":"7","key":"3843_CR42","first-page":"524","volume":"39","author":"JB Lu","year":"2016","unstructured":"Lu JB et al (2016) Analysis of Koch phenomenon of Mycobacterium tuberculosis-infected guinea pigs vaccinated with recombinant tuberculosis vaccine AEC\/BC02. Zhonghua Jie He He Hu Xi Za Zhi 39(7):524\u2013528","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"3843_CR43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.meegid.2017.09.023","volume":"55","author":"AP Perez-Martinez","year":"2017","unstructured":"Perez-Martinez AP et al (2017) Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa. Infect Genet Evol 55:244\u2013250","journal-title":"Infect Genet Evol"},{"issue":"1","key":"3843_CR44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","volume":"122","author":"PL Lin","year":"2012","unstructured":"Lin PL et al (2012) The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 122(1):303\u2013314","journal-title":"J Clin Invest"},{"issue":"2","key":"3843_CR45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.201802-0366OC","volume":"199","author":"S Suliman","year":"2019","unstructured":"Suliman S et al (2019) Dose optimization of H56:IC31 vaccine for tuberculosis-endemic populations. A double-blind, placebo-controlled, dose-selection trial. Am J Respir Crit Care Med 199(2):220\u2013231","journal-title":"Am J Respir Crit Care Med"},{"issue":"33","key":"3843_CR46","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","volume":"33","author":"AK Luabeya","year":"2015","unstructured":"Luabeya AK et al (2015) First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 33(33):4130\u20134140","journal-title":"Vaccine"},{"issue":"1","key":"3843_CR47","doi-asserted-by":"crossref","first-page":"e83884","DOI":"10.1371\/journal.pone.0083884","volume":"9","author":"MT Orr","year":"2014","unstructured":"Orr MT et al (2014) A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS One 9(1):e83884","journal-title":"PLoS One"},{"issue":"9","key":"3843_CR48","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1128\/IAI.02145-14","volume":"82","author":"MS Duthie","year":"2014","unstructured":"Duthie MS et al (2014) Protection against Mycobacterium leprae infection by the ID83\/GLA-SE and ID93\/GLA-SE vaccines developed for tuberculosis. Infect Immun 82(9):3979\u20133985","journal-title":"Infect Immun"},{"issue":"53","key":"3843_CR49","doi-asserted-by":"crossref","first-page":"53ra74","DOI":"10.1126\/scitranslmed.3001094","volume":"2","author":"S Bertholet","year":"2010","unstructured":"Bertholet S et al (2010) A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2(53):53ra74","journal-title":"Sci Transl Med"},{"issue":"5","key":"3843_CR50","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","volume":"188","author":"SL Baldwin","year":"2012","unstructured":"Baldwin SL et al (2012) The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188(5):2189\u20132197","journal-title":"J Immunol"},{"issue":"2","key":"3843_CR51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/CVI.00458-15","volume":"23","author":"SL Baldwin","year":"2016","unstructured":"Baldwin SL et al (2016) Protection and long-lived immunity induced by the ID93\/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate. Clin Vaccine Immunol 23(2):137\u2013147","journal-title":"Clin Vaccine Immunol"},{"issue":"19","key":"3843_CR52","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.vaccine.2016.03.029","volume":"34","author":"SB Cha","year":"2016","unstructured":"Cha SB et al (2016) Pulmonary immunity and durable protection induced by the ID93\/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K. Vaccine 34(19):2179\u20132187","journal-title":"Vaccine"},{"issue":"8","key":"3843_CR53","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/infdis\/jis425","volume":"207","author":"RN Coler","year":"2013","unstructured":"Coler RN et al (2013) Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 207(8):1242\u20131252","journal-title":"J Infect Dis"},{"issue":"9","key":"3843_CR54","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/CVI.00372-14","volume":"21","author":"SL Baldwin","year":"2014","unstructured":"Baldwin SL et al (2014) The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative. Clin Vaccine Immunol 21(9):1309\u20131313","journal-title":"Clin Vaccine Immunol"},{"key":"3843_CR55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41541-018-0057-5","volume":"3","author":"RN Coler","year":"2018","unstructured":"Coler RN et al (2018) The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines 3:34","journal-title":"NPJ Vaccines"},{"issue":"4","key":"3843_CR56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","volume":"6","author":"A Penn-Nicholson","year":"2018","unstructured":"Penn-Nicholson A et al (2018) Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 6(4):287\u2013298","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3843_CR57","doi-asserted-by":"crossref","first-page":"e0152200","DOI":"10.1371\/journal.pone.0152200","volume":"11","author":"S Homolka","year":"2016","unstructured":"Homolka S, Ubben T, Niemann S (2016) High sequence variability of the ppE18 gene of clinical Mycobacterium tuberculosis complex strains potentially impacts effectivity of vaccine candidate M72\/AS01E. PLoS One 11(3):e0152200","journal-title":"PLoS One"},{"issue":"8","key":"3843_CR58","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s10875-013-9949-3","volume":"33","author":"J Montoya","year":"2013","unstructured":"Montoya J et al (2013) A randomized, controlled dose-finding phase II study of the M72\/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol 33(8):1360\u20131375","journal-title":"J Clin Immunol"},{"issue":"8","key":"3843_CR59","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1128\/IAI.67.8.3998-4007.1999","volume":"67","author":"YA Skeiky","year":"1999","unstructured":"Skeiky YA et al (1999) Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 67(8):3998\u20134007","journal-title":"Infect Immun"},{"issue":"6","key":"3843_CR60","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/IAI.67.6.2941-2950.1999","volume":"67","author":"DC Dillon","year":"1999","unstructured":"Dillon DC et al (1999) Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 67(6):2941\u20132950","journal-title":"Infect Immun"},{"issue":"1","key":"3843_CR61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2249.2004.02609.x","volume":"138","author":"R Al-Attiyah","year":"2004","unstructured":"Al-Attiyah R et al (2004) In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 138(1):139\u2013144","journal-title":"Clin Exp Immunol"},{"issue":"Suppl 1","key":"3843_CR62","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-14-S1-S2","volume":"14","author":"C Montagnani","year":"2014","unstructured":"Montagnani C et al (2014) Vaccine against tuberculosis: what's new? BMC Infect Dis 14(Suppl 1):S2","journal-title":"BMC Infect Dis"},{"issue":"1","key":"3843_CR63","first-page":"61","volume":"14","author":"MS Nabavinia","year":"2012","unstructured":"Nabavinia MS et al (2012) Construction of an expression vector containing Mtb72F of Mycobacterium tuberculosis. Cell J 14(1):61\u201366","journal-title":"Cell J"},{"issue":"12","key":"3843_CR64","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","volume":"172","author":"YA Skeiky","year":"2004","unstructured":"Skeiky YA et al (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172(12):7618\u20137628","journal-title":"J Immunol"},{"issue":"4","key":"3843_CR65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1164\/rccm.201208-1385OC","volume":"188","author":"CL Day","year":"2013","unstructured":"Day CL et al (2013) Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72\/AS01 in south African adults. Am J Respir Crit Care Med 188(4):492\u2013502","journal-title":"Am J Respir Crit Care Med"},{"key":"3843_CR66","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","volume":"100","author":"P Gillard","year":"2016","unstructured":"Gillard P et al (2016) Safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in adults with tuberculosis: a phase II randomised study. Tuberculosis (Edinb) 100:118\u2013127","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"3843_CR67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","volume":"94","author":"OT Idoko","year":"2014","unstructured":"Idoko OT et al (2014) Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb) 94(6):564\u2013578","journal-title":"Tuberculosis (Edinb)"},{"issue":"3","key":"3843_CR68","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002459","volume":"95","author":"N Kumarasamy","year":"2016","unstructured":"Kumarasamy N et al (2016) A randomized, controlled safety, and immunogenicity trial of the M72\/AS01 candidate tuberculosis vaccine in HIV-positive Indian adults. Medicine (Baltimore) 95(3):e2459","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"3843_CR69","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","volume":"31","author":"I Leroux-Roels","year":"2013","unstructured":"Leroux-Roels I et al (2013) Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31(17):2196\u20132206","journal-title":"Vaccine"},{"issue":"32","key":"3843_CR70","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","volume":"33","author":"A Penn-Nicholson","year":"2015","unstructured":"Penn-Nicholson A et al (2015) Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting. Vaccine 33(32):4025\u20134034","journal-title":"Vaccine"},{"issue":"12","key":"3843_CR71","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/QAD.0000000000000343","volume":"28","author":"EG Thacher","year":"2014","unstructured":"Thacher EG et al (2014) Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I\/II, randomized trial. AIDS 28(12):1769\u20131781","journal-title":"AIDS"},{"issue":"45","key":"3843_CR72","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1097\/MD.0000000000013120","volume":"97","author":"N Kumarasamy","year":"2018","unstructured":"Kumarasamy N et al (2018) Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: results from a phase II randomized controlled trial. Medicine (Baltimore) 97(45):S","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"3843_CR73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren O et al (2018) Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis. N Engl J Med 379(17):1621\u20131634","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"3843_CR74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","volume":"86","author":"PJ Cardona","year":"2006","unstructured":"Cardona PJ (2006) RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 86(3\u20134):273\u2013289","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"3843_CR75","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","volume":"28","author":"C Vilaplana","year":"2010","unstructured":"Vilaplana C et al (2010) Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28(4):1106\u20131116","journal-title":"Vaccine"},{"issue":"2","key":"3843_CR76","doi-asserted-by":"crossref","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","volume":"9","author":"AS Nell","year":"2014","unstructured":"Nell AS et al (2014) Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One 9(2):e89612","journal-title":"PLoS One"},{"issue":"5","key":"3843_CR77","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","volume":"24","author":"CF von Reyn","year":"2010","unstructured":"von Reyn CF et al (2010) Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5):675\u2013685","journal-title":"AIDS"},{"issue":"12","key":"3843_CR78","doi-asserted-by":"crossref","first-page":"e0168521","DOI":"10.1371\/journal.pone.0168521","volume":"11","author":"T Lahey","year":"2016","unstructured":"Lahey T et al (2016) Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PLoS One 11(12):e0168521","journal-title":"PLoS One"},{"issue":"5","key":"3843_CR79","doi-asserted-by":"crossref","first-page":"e0175215","DOI":"10.1371\/journal.pone.0175215","volume":"12","author":"CF von Reyn","year":"2017","unstructured":"von Reyn CF et al (2017) Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS One 12(5):e0175215","journal-title":"PLoS One"},{"issue":"5","key":"3843_CR80","doi-asserted-by":"crossref","first-page":"e0217091","DOI":"10.1371\/journal.pone.0217091","volume":"14","author":"T Masonou","year":"2019","unstructured":"Masonou T et al (2019) CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial. PLoS One 14(5):e0217091","journal-title":"PLoS One"},{"issue":"1","key":"3843_CR81","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12889-018-5460-3","volume":"18","author":"SR Craig","year":"2018","unstructured":"Craig SR et al (2018) Altruism, scepticism, and collective decision-making in foreign-born U.S. residents in a tuberculosis vaccine trial. BMC Public Health 18(1):535","journal-title":"BMC Public Health"},{"issue":"3","key":"3843_CR82","first-page":"250","volume":"67","author":"P Sharma","year":"1999","unstructured":"Sharma P et al (1999) Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine. Int J Lepr Other Mycobact Dis 67(3):250\u2013258","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"2","key":"3843_CR83","doi-asserted-by":"crossref","first-page":"127","DOI":"10.47276\/lr.76.2.127","volume":"76","author":"P Sharma","year":"2005","unstructured":"Sharma P et al (2005) Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years. Lepr Rev 76(2):127\u2013143","journal-title":"Lepr Rev"},{"issue":"2","key":"3843_CR84","first-page":"179","volume":"71","author":"P Sharma","year":"2000","unstructured":"Sharma P et al (2000) Mycobacterium w vaccine, a useful adjuvant to multidrug therapy in multibacillary leprosy: a report on hospital based immunotherapeutic clinical trials with a follow-up of 1-7 years after treatment. Lepr Rev 71(2):179\u2013192","journal-title":"Lepr Rev"},{"issue":"3","key":"3843_CR85","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00190265","volume":"182","author":"I Guleria","year":"1993","unstructured":"Guleria I, Mukherjee R, Kaufmann SH (1993) In vivo depletion of CD4 and CD8 T lymphocytes impairs Mycobacterium w vaccine-induced protection against M. tuberculosis in mice. Med Microbiol Immunol 182(3):129\u2013135","journal-title":"Med Microbiol Immunol"},{"issue":"43","key":"3843_CR86","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1016\/j.vaccine.2012.07.061","volume":"30","author":"A Gupta","year":"2012","unstructured":"Gupta A et al (2012) Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine 30(43):6198\u20136209","journal-title":"Vaccine"},{"issue":"3","key":"3843_CR87","first-page":"191","volume":"100","author":"N Patel","year":"2002","unstructured":"Patel N, Deshpande MM, Shah M (2002) Effect of an immunomodulator containing Mycobacterium w on sputum conversion in pulmonary tuberculosis. J Indian Med Assoc 100(3):191\u2013193","journal-title":"J Indian Med Assoc"},{"issue":"11","key":"3843_CR88","first-page":"680","volume":"101","author":"N Patel","year":"2003","unstructured":"Patel N, Trapathi SB (2003) Improved cure rates in pulmonary tuberculosis category II (retreatment) with mycobacterium w. J Indian Med Assoc 101(11):680 682","journal-title":"J Indian Med Assoc"},{"issue":"26","key":"3843_CR89","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2014.03.047","volume":"32","author":"MI Groschel","year":"2014","unstructured":"Groschel MI et al (2014) Therapeutic vaccines for tuberculosis--a systematic review. Vaccine 32(26):3162\u20133168","journal-title":"Vaccine"},{"key":"3843_CR90","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3389\/fimmu.2017.01803","volume":"8","author":"J Gonzalo-Asensio","year":"2017","unstructured":"Gonzalo-Asensio J et al (2017) MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic. Front Immunol 8:1803","journal-title":"Front Immunol"},{"key":"3843_CR91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tube.2015.10.010","volume":"96","author":"N Aguilo","year":"2016","unstructured":"Aguilo N et al (2016) MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice. Tuberculosis (Edinb) 96:71\u201374","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"3843_CR92","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2017.1324303","volume":"16","author":"D Marinova","year":"2017","unstructured":"Marinova D et al (2017) MTBVAC from discovery to clinical trials in tuberculosis-endemic countries. Expert Rev Vaccines 16(6):565\u2013576","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"3843_CR93","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","volume":"3","author":"F Spertini","year":"2015","unstructured":"Spertini F et al (2015) Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 3(12):953\u2013962","journal-title":"Lancet Respir Med"},{"key":"3843_CR94","volume-title":"Global tuberculosis program and global program on vaccine: statement on BCG revaccination for the prevention of tuberculosis","author":"World Health Organization","year":"1995","unstructured":"World Health Organization (1995) Global tuberculosis program and global program on vaccine: statement on BCG revaccination for the prevention of tuberculosis. WHO, Geneva"},{"key":"3843_CR95","volume-title":"BCG vaccine. WHO position paper","author":"World Health Organization","year":"2004","unstructured":"World Health Organization (2004) BCG vaccine. WHO position paper. WHO, Geneva"},{"key":"3843_CR96","volume-title":"BCG vaccines: WHO position paper-February 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization (2018) BCG vaccines: WHO position paper-February 2018. WHO, Geneva"},{"key":"3843_CR97","volume-title":"Revised BCG vaccination guidelines for infants at risk for HIV infection","author":"World Health Organization","year":"2007","unstructured":"World Health Organization (2007) Revised BCG vaccination guidelines for infants at risk for HIV infection. WHO, Geneva"},{"issue":"1","key":"3843_CR98","first-page":"7","volume":"49","author":"AA Husain","year":"2011","unstructured":"Husain AA et al (2011) Effect of repeat dose of BCG vaccination on humoral response in mice model. Indian J Exp Biol 49(1):7\u201310","journal-title":"Indian J Exp Biol"},{"issue":"1","key":"3843_CR99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7774\/cevr.2015.4.1.83","volume":"4","author":"AA Husain","year":"2015","unstructured":"Husain AA et al (2015) Comparative evaluation of booster efficacies of BCG, Ag85B, and Ag85B peptides based vaccines to boost BCG induced immunity in BALB\/c mice: a pilot study. Clin Exp Vaccine Res 4(1):83\u201387","journal-title":"Clin Exp Vaccine Res"},{"issue":"9","key":"3843_CR100","doi-asserted-by":"crossref","first-page":"e106519","DOI":"10.1371\/journal.pone.0106519","volume":"9","author":"NA Parlane","year":"2014","unstructured":"Parlane NA et al (2014) Revaccination of cattle with bacille Calmette-Guerin two years after first vaccination when immunity has waned, boosted protection against challenge with Mycobacterium bovis. PLoS One 9(9):e106519","journal-title":"PLoS One"},{"key":"3843_CR101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-8518-8-3","volume":"8","author":"RS Kashyap","year":"2010","unstructured":"Kashyap RS et al (2010) Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model. J Immune Based Ther Vaccines 8:3","journal-title":"J Immune Based Ther Vaccines"},{"issue":"2","key":"3843_CR102","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes E et al (2018) Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 379(2):138\u2013149","journal-title":"N Engl J Med"},{"key":"3843_CR103","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","volume":"8","author":"NE Nieuwenhuizen","year":"2017","unstructured":"Nieuwenhuizen NE et al (2017) The recombinant Bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol 8:1147","journal-title":"Front Immunol"},{"issue":"8","key":"3843_CR104","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.tim.2012.04.006","volume":"20","author":"MA Hamon","year":"2012","unstructured":"Hamon MA et al (2012) Listeriolysin O: the Swiss army knife of Listeria. Trends Microbiol 20(8):360\u2013368","journal-title":"Trends Microbiol"},{"issue":"5","key":"3843_CR105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1462-5822.2005.00665.x","volume":"8","author":"LM Shaughnessy","year":"2006","unstructured":"Shaughnessy LM et al (2006) Membrane perforations inhibit lysosome fusion by altering pH and calcium in Listeria monocytogenes vacuoles. Cell Microbiol 8(5):781\u2013792","journal-title":"Cell Microbiol"},{"issue":"19","key":"3843_CR106","doi-asserted-by":"crossref","first-page":"8768","DOI":"10.1073\/pnas.92.19.8768","volume":"92","author":"JM Reyrat","year":"1995","unstructured":"Reyrat JM, Berthet FX, Gicquel B (1995) The urease locus of Mycobacterium tuberculosis and its utilization for the demonstration of allelic exchange in Mycobacterium bovis bacillus Calmette-Guerin. Proc Natl Acad Sci U S A 92(19):8768\u20138772","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5768","key":"3843_CR107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/286079a0","volume":"286","author":"AH Gordon","year":"1980","unstructured":"Gordon AH, Hart PD, Young MR (1980) Ammonia inhibits phagosome-lysosome fusion in macrophages. Nature 286(5768):79\u201380","journal-title":"Nature"},{"issue":"5","key":"3843_CR108","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/14760584.2014.905746","volume":"13","author":"SH Kaufmann","year":"2014","unstructured":"Kaufmann SH et al (2014) The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 13(5):619\u2013630","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"3843_CR109","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","volume":"31","author":"L Grode","year":"2013","unstructured":"Grode L et al (2013) Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 31(9):1340\u20131348","journal-title":"Vaccine"},{"key":"3843_CR110","doi-asserted-by":"publisher","unstructured":"Loxton AG,Knaul JK,Grode L,Gutschmidt A,Meller C,Eisele B,Johnstone H,van der Spuy G,Maertzdorf J,Kaufmann SHE,Hesseling AC,Walzl G,Cotton MF., Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa. Clin Vaccine Immunol. 2017 Feb 6;24(2). pii: e00439-16. https:\/\/doi.org\/10.1128\/CVI.00439-16. Print 2017 Feb","DOI":"10.1128\/CVI.00439-16"},{"issue":"12","key":"3843_CR111","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.4049\/jimmunol.1300248","volume":"190","author":"T Lindenstrom","year":"2013","unstructured":"Lindenstrom T et al (2013) Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. J Immunol 190(12):6311\u20136319","journal-title":"J Immunol"},{"issue":"9","key":"3843_CR112","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","volume":"115","author":"L Grode","year":"2005","unstructured":"Grode L et al (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115(9):2472\u20132479","journal-title":"J Clin Invest"},{"issue":"10","key":"3843_CR113","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jir592","volume":"204","author":"C Desel","year":"2011","unstructured":"Desel C et al (2011) Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204(10):1573\u20131584","journal-title":"J Infect Dis"},{"issue":"12","key":"3843_CR114","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/infdis\/jiu347","volume":"210","author":"A Vogelzang","year":"2014","unstructured":"Vogelzang A et al (2014) Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guerin DeltaureC::hly vaccine's superior protection against tuberculosis. J Infect Dis 210(12):1928\u20131937","journal-title":"J Infect Dis"},{"issue":"5","key":"3843_CR115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.micinf.2016.03.005","volume":"18","author":"M Gengenbacher","year":"2016","unstructured":"Gengenbacher M et al (2016) Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guerin DeltaureC::hly induces superior protection in a mouse model of subclinical tuberculosis. Microbes Infect 18(5):364\u2013368","journal-title":"Microbes Infect"},{"key":"3843_CR116","doi-asserted-by":"publisher","unstructured":"Gengenbacher M, Nieuwenhuizen N, Vogelzang A, Liu H, Kaiser P, Schuerer S, Lazar D, Wagner I, Mollenkopf HJ, Kaufmann SH., Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG DeltaureC::hly Improves Protection against Tuberculosis. mBio.2016 May 24;7(3). pii: e00679-16. https:\/\/doi.org\/10.1128\/mBio.00679-16","DOI":"10.1128\/mBio.00679-16"},{"issue":"2","key":"3843_CR117","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/vaccines1020120","volume":"1","author":"K Velmurugan","year":"2013","unstructured":"Velmurugan K et al (2013) Nonclinical development of BCG replacement vaccine candidates. Vaccines (Basel) 1(2):120\u2013138","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"3843_CR118","doi-asserted-by":"crossref","first-page":"5809","DOI":"10.1128\/IAI.73.9.5809-5816.2005","volume":"73","author":"SM Irwin","year":"2005","unstructured":"Irwin SM et al (2005) Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 73(9):5809\u20135816","journal-title":"Infect Immun"},{"issue":"11","key":"3843_CR119","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1128\/IAI.72.11.6622-6632.2004","volume":"72","author":"L Brandt","year":"2004","unstructured":"Brandt L et al (2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72(11):6622\u20136632","journal-title":"Infect Immun"},{"issue":"4","key":"3843_CR120","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/IAI.74.4.2392-2401.2006","volume":"74","author":"L Tsenova","year":"2006","unstructured":"Tsenova L et al (2006) Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 74(4):2392\u20132401","journal-title":"Infect Immun"},{"issue":"7","key":"3843_CR121","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1073\/pnas.0712077106","volume":"106","author":"SG Reed","year":"2009","unstructured":"Reed SG et al (2009) Defined tuberculosis vaccine, Mtb72F\/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A 106(7):2301\u20132306","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3843_CR122","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.coi.2009.06.004","volume":"21","author":"AM Cooper","year":"2009","unstructured":"Cooper AM et al (2009) T cells in mycobacterial infection and disease. Curr Opin Immunol 21(4):378\u2013384","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"3843_CR123","doi-asserted-by":"crossref","first-page":"e63331","DOI":"10.1371\/journal.pone.0063331","volume":"8","author":"VE Calderon","year":"2013","unstructured":"Calderon VE et al (2013) A humanized mouse model of tuberculosis. PLoS One 8(5):e63331","journal-title":"PLoS One"},{"issue":"29","key":"3843_CR124","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1016\/j.vaccine.2014.05.005","volume":"32","author":"S Commandeur","year":"2014","unstructured":"Commandeur S et al (2014) The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and Guinea pigs. Vaccine 32(29):3580\u20133588","journal-title":"Vaccine"},{"key":"3843_CR125","doi-asserted-by":"crossref","first-page":"21522","DOI":"10.1038\/srep21522","volume":"6","author":"RJ Nusbaum","year":"2016","unstructured":"Nusbaum RJ et al (2016) Pulmonary tuberculosis in humanized mice infected with HIV-1. Sci Rep 6:21522","journal-title":"Sci Rep"},{"issue":"2","key":"3843_CR126","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1128\/AAC.02637-15","volume":"60","author":"JP Lanoix","year":"2015","unstructured":"Lanoix JP et al (2015) Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB\/FeJ mouse model of tuberculosis. Antimicrob Agents Chemother 60(2):1091\u20131096","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3843_CR127","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1242\/dmm.019513","volume":"8","author":"JP Lanoix","year":"2015","unstructured":"Lanoix JP et al (2015) Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis. Dis Model Mech 8(6):603\u2013610","journal-title":"Dis Model Mech"},{"issue":"2","key":"3843_CR128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nm.2285","volume":"17","author":"C Aagaard","year":"2011","unstructured":"Aagaard C et al (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17(2):189\u2013194","journal-title":"Nat Med"},{"issue":"4","key":"3843_CR129","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ijmyco.2015.05.015","volume":"4","author":"RE Jacobs","year":"2015","unstructured":"Jacobs RE et al (2015) Reactivation of pulmonary tuberculosis during cancer treatment. Int J Mycobacteriol 4(4):337\u2013340","journal-title":"Int J Mycobacteriol"},{"issue":"14\u201315","key":"3843_CR130","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.micinf.2008.08.010","volume":"10","author":"SS Kashino","year":"2008","unstructured":"Kashino SS et al (2008) Guinea pig model of Mycobacterium tuberculosis latent\/dormant infection. Microbes Infect 10(14\u201315):1469\u20131476","journal-title":"Microbes Infect"},{"issue":"5","key":"3843_CR131","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1128\/AAC.01521-09","volume":"54","author":"DJ Ordway","year":"2010","unstructured":"Ordway DJ et al (2010) Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother 54(5):1820\u20131833","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3843_CR132","doi-asserted-by":"crossref","first-page":"a018572","DOI":"10.1101\/cshperspect.a018572","volume":"5","author":"S Clark","year":"2014","unstructured":"Clark S et al (2014) Animal models of tuberculosis: guinea pigs. Cold Spring Harb Perspect Med 5(5):a018572","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"11","key":"3843_CR133","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1128\/IAI.64.11.4776-4787.1996","volume":"64","author":"PJ Converse","year":"1996","unstructured":"Converse PJ et al (1996) Cavitary tuberculosis produced in rabbits by aerosolized virulent tubercle bacilli. Infect Immun 64(11):4776\u20134787","journal-title":"Infect Immun"},{"issue":"3","key":"3843_CR134","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4161\/viru.1.3.11748","volume":"1","author":"G Zhang","year":"2010","unstructured":"Zhang G et al (2010) Evaluation of mycobacterial virulence using rabbit skin liquefaction model. Virulence 1(3):156\u2013163","journal-title":"Virulence"},{"issue":"4","key":"3843_CR135","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tube.2009.05.006","volume":"89","author":"AM Dannenberg Jr","year":"2009","unstructured":"Dannenberg AM Jr (2009) Liquefaction and cavity formation in pulmonary TB: a simple method in rabbit skin to test inhibitors. Tuberculosis (Edinb) 89(4):243\u2013247","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"3843_CR136","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.tube.2012.03.005","volume":"92","author":"H Sun","year":"2012","unstructured":"Sun H et al (2012) Effects of immunomodulators on liquefaction and ulceration in the rabbit skin model of tuberculosis. Tuberculosis (Edinb) 92(4):345\u2013350","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"3843_CR137","first-page":"499","volume":"65","author":"X Peng","year":"2015","unstructured":"Peng X et al (2015) Rabbit models for studying human infectious diseases. Comp Med 65(6):499\u2013507","journal-title":"Comp Med"},{"issue":"3","key":"3843_CR138","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tube.2007.10.006","volume":"88","author":"YC Manabe","year":"2008","unstructured":"Manabe YC et al (2008) The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. Tuberculosis (Edinb) 88(3):187\u2013196","journal-title":"Tuberculosis (Edinb)"},{"issue":"1","key":"3843_CR139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4184\/asj.2016.10.1.1","volume":"10","author":"AJ Rahyussalim","year":"2016","unstructured":"Rahyussalim AJ et al (2016) New bone formation in tuberculous-infected vertebral body defect after administration of bone marrow stromal cells in rabbit model. Asian Spine J 10(1):1\u20135","journal-title":"Asian Spine J"},{"issue":"9","key":"3843_CR140","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1128\/IAI.67.9.4531-4538.1999","volume":"67","author":"CA Scanga","year":"1999","unstructured":"Scanga CA et al (1999) Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 67(9):4531\u20134538","journal-title":"Infect Immun"},{"issue":"11","key":"3843_CR141","doi-asserted-by":"crossref","first-page":"e0143552","DOI":"10.1371\/journal.pone.0143552","volume":"10","author":"AA Izzo","year":"2015","unstructured":"Izzo AA et al (2015) A novel MVA-based multiphasic vaccine for prevention or treatment of tuberculosis induces broad and multifunctional cell-mediated immunity in mice and primates. PLoS One 10(11):e0143552","journal-title":"PLoS One"},{"issue":"3","key":"3843_CR142","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/IAI.02850-14","volume":"83","author":"JC Pena","year":"2015","unstructured":"Pena JC et al (2015) Monkey models of tuberculosis: lessons learned. Infect Immun 83(3):852\u2013862","journal-title":"Infect Immun"},{"issue":"5","key":"3843_CR143","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1128\/IAI.00083-16","volume":"84","author":"J Phuah","year":"2016","unstructured":"Phuah J et al (2016) Effects of B cell depletion on early Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 84(5):1301\u20131311","journal-title":"Infect Immun"},{"issue":"10","key":"3843_CR144","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1128\/IAI.00592-09","volume":"77","author":"PL Lin","year":"2009","unstructured":"Lin PL et al (2009) Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 77(10):4631\u20134642","journal-title":"Infect Immun"},{"issue":"3","key":"3843_CR145","doi-asserted-by":"crossref","first-page":"e9611","DOI":"10.1371\/journal.pone.0009611","volume":"5","author":"CR Diedrich","year":"2010","unstructured":"Diedrich CR et al (2010) Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load. PLoS One 5(3):e9611","journal-title":"PLoS One"},{"issue":"6062","key":"3843_CR146","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.334.6062.1488","volume":"334","author":"K Kupferschmidt","year":"2011","unstructured":"Kupferschmidt K (2011) Infectious disease. Taking a new shot at a TB vaccine. Science 334(6062):1488\u20131490","journal-title":"Science"},{"issue":"11","key":"3843_CR147","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","volume":"10","author":"H McShane","year":"2004","unstructured":"McShane H et al (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10(11):1240\u20131244","journal-title":"Nat Med"},{"issue":"4","key":"3843_CR148","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","volume":"4","author":"FA Verreck","year":"2009","unstructured":"Verreck FA et al (2009) MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4(4):e5264","journal-title":"PLoS One"},{"issue":"11","key":"3843_CR149","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/eji.200737504","volume":"37","author":"NE Beveridge","year":"2007","unstructured":"Beveridge NE et al (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37(11):3089\u20133100","journal-title":"Eur J Immunol"},{"issue":"2","key":"3843_CR150","doi-asserted-by":"crossref","first-page":"e000223","DOI":"10.1136\/bmjopen-2011-000223","volume":"1","author":"AM Minassian","year":"2011","unstructured":"Minassian AM et al (2011) A phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open 1(2):e000223","journal-title":"BMJ Open"},{"issue":"38","key":"3843_CR151","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1016\/j.vaccine.2012.06.054","volume":"30","author":"AA Odutola","year":"2012","unstructured":"Odutola AA et al (2012) A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants. Vaccine 30(38):5591\u20135594","journal-title":"Vaccine"},{"issue":"38","key":"3843_CR152","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1016\/j.vaccine.2012.06.084","volume":"30","author":"AA Pathan","year":"2012","unstructured":"Pathan AA et al (2012) Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine 30(38):5616\u20135624","journal-title":"Vaccine"},{"issue":"8","key":"3843_CR153","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1164\/rccm.200809-1486OC","volume":"179","author":"CR Sander","year":"2009","unstructured":"Sander CR et al (2009) Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med 179(8):724\u2013733","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3843_CR154","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/eji.200939754","volume":"40","author":"TJ Scriba","year":"2010","unstructured":"Scriba TJ et al (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40(1):279\u2013290","journal-title":"Eur J Immunol"},{"issue":"12","key":"3843_CR155","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/infdis\/jir195","volume":"203","author":"TJ Scriba","year":"2011","unstructured":"Scriba TJ et al (2011) Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 203(12):1832\u20131843","journal-title":"J Infect Dis"},{"issue":"7","key":"3843_CR156","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1164\/rccm.201108-1548OC","volume":"185","author":"TJ Scriba","year":"2012","unstructured":"Scriba TJ et al (2012) A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and\/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 185(7):769\u2013778","journal-title":"Am J Respir Crit Care Med"},{"issue":"9871","key":"3843_CR157","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris MD et al (2013) Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381(9871):1021\u20131028","journal-title":"Lancet"},{"issue":"6685","key":"3843_CR158","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/31159","volume":"393","author":"ST Cole","year":"1998","unstructured":"Cole ST et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685):537\u2013544","journal-title":"Nature"},{"issue":"8","key":"3843_CR159","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1473-3099(11)70146-3","volume":"11","author":"SH Kaufmann","year":"2011","unstructured":"Kaufmann SH (2011) Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 11(8):633\u2013640","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"3843_CR160","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1128\/CVI.00721-14","volume":"22","author":"K Bhatt","year":"2015","unstructured":"Bhatt K et al (2015) Quest for correlates of protection against tuberculosis. Clin Vaccine Immunol 22(3):258\u2013266","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"3843_CR161","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.coi.2009.05.017","volume":"21","author":"LF Barker","year":"2009","unstructured":"Barker LF et al (2009) Tuberculosis vaccine research: the impact of immunology. Curr Opin Immunol 21(3):331\u2013338","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3843_CR162","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.coi.2009.06.004","volume":"21","author":"AM Cooper","year":"2009","unstructured":"Cooper AM (2009) T cells in mycobacterial infection and disease. Curr Opin Immunol 21(4):378\u2013384","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"3843_CR163","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tube.2009.08.004","volume":"89","author":"A Williams","year":"2009","unstructured":"Williams A, Hall Y, Orme IM (2009) Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb) 89(6):389\u2013397","journal-title":"Tuberculosis (Edinb)"},{"issue":"1\u20133","key":"3843_CR164","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1472-9792(02)00080-X","volume":"83","author":"SG Reed","year":"2003","unstructured":"Reed SG et al (2003) Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 83(1\u20133):213\u2013219","journal-title":"Tuberculosis (Edinb)"},{"issue":"5","key":"3843_CR165","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1164\/rccm.201203-0444OC","volume":"186","author":"KP Fennelly","year":"2012","unstructured":"Fennelly KP et al (2012) Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 186(5):450\u2013457","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-020-03843-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T18:33:51Z","timestamp":1667327631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-020-03843-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":165,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["3843"],"URL":"https:\/\/doi.org\/10.1007\/s10096-020-03843-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,15]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was supported by the National Science and Technology Major Project for Infectious Diseases Control and Prevention (No.2017ZX10201301\u2013006) and CAMS Major Innovation Funding For Medical Science (2016-I2M-2-006).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}